Adams Respiratory Therapeutics, Inc. (1319439) SEC Filing 10-K Annual report for the fiscal year ending Thursday, June 30, 2005

Adams Respiratory Therapeutics, Inc.

CIK: 1319439

Exhibit 99.1

Adams Respiratory Therapeutics Reports
Fourth Quarter and Fiscal Year-End 2005 Results
Fiscal Year 2005 Highlights:
  Net sales increased by $98.9 million to $160.2 million
  Pretax income increased 126 percent to $44.4 million
  Net income of $27.0 million; Pro forma diluted EPS of $0.95
  Launched Mucinex DM in August 2004
  Initiated major direct-to-consumer advertising campaign for Mucinex
  Doubled the size of the professional sales force
CHESTER, N.J. (Sept. 19, 2005) – Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT), today announced financial results for the fourth quarter and fiscal year ended June 30, 2005.
“Fiscal 2005 was a watershed year for Adams on many fronts,” said Michael J. Valentino, president and CEO of Adams. “We launched our second product, Mucinex DM, initiated a major consumer advertising and marketing campaign for Mucinex as well as made significant strides in the quality and depth of retail distribution of the brand. In addition, we made preparations for an initial public equity offering, among other notable events,” added Valentino. In July, the Company completed a successful public offering generating more than $117 million in equity funding.
Fiscal Year 2005 Results
The Company’s net sales of $160.2 million in the 2005 fiscal year grew 161 percent from $61.3 million in fiscal year 2004. Net sales of Mucinex SE rose more than 120 percent to $117.4 million from sales of $52.9 million in the prior fiscal year, benefiting from a new direct-to-consumer advertising campaign that was initiated in November 2004. Launched in August 2004, Mucinex DM had fiscal 2005 sales of $38.3 million.
Pretax income for the fiscal year 2005 was $44.4 million, a 126 percent increase from pretax income of $19.7 million in the 2004 fiscal period.


The following information was filed by Adams Respiratory Therapeutics, Inc. on Monday, September 19, 2005 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Adams Respiratory Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adams Respiratory Therapeutics, Inc..


Assess how Adams Respiratory Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adams Respiratory Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2005 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 1319439
Form Type: 10-K Annual Report
Accession Number: 0000950123-05-011561
Submitted to the SEC: Tue Sep 27 2005 7:09:56 PM EST
Accepted by the SEC: Wed Sep 28 2005
Period: Thursday, June 30, 2005
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink: